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Abstract  
Background Exercise for Health was a pragmatic, randomised, controlled trial 
comparing the effect of an eight-month exercise intervention on function, treatment-
related side effects and quality of life following breast cancer, compared with usual 
care.  The intervention commenced six weeks post-surgery, and two modes of 
delivering the same intervention was compared with usual care.  The purpose of this 
paper is to describe the study design, along with outcomes related to recruitment, 
retention and representativeness, and intervention participation. 
Methods: Women newly diagnosed with breast cancer and residing in a major 
metropolitan city of Queensland, Australia, were eligible to participate.  Consenting 
women were randomised to a face-to-face-delivered exercise group (FtF, n=67), 
telephone-delivered exercise group (Tel, n=67) or usual care group (UC, n=60) and 
were assessed pre-intervention (5-weeks post-surgery), mid-intervention (6 months 
post-surgery) and 10 weeks post-intervention (12 months post-surgery).  Each 
intervention arm entailed 16 sessions with an Exercise Physiologist. 
Results: Of 318 potentially eligible women, 63% (n=200) agreed to participate, with a 
12-month retention rate of 93%. Participants were similar to the Queensland breast 
cancer population with respect to disease characteristics, and the randomisation 
procedure was mostly successful at attaining group balance, with the few minor 
imbalances observed unlikely to influence intervention effects given balance in other 
related characteristics.  Median participation was 14 (min, max: 0, 16) and 13 (min, 
max: 3, 16) intervention sessions for the FtF and Tel, respectively, with 68% of those 
in Tel and 82% in FtF participating in at least 75% of sessions.   
Discussion: Participation in both intervention arms during and following treatment for 
breast cancer was feasible and acceptable to women.  Future work, designed to inform 
translation into practice, will evaluate the quality of life, clinical, psychosocial and 
behavioural outcomes associated with each mode of delivery.   
 
Keywords: Breast cancer, Exercise, Rehabilitation, Randomised controlled trial, 
Physical activity  
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1. Introduction  
As survival rates following breast cancer have improved [1], so too has our 
understanding of the diverse physical and psychosocial side-effects that occur during 
and following treatment. Findings from studies on women following a diagnosis of 
breast cancer highlight that treatment-related side-effects are common, especially 
fatigue, pain and upper-body morbidity [2-5], and are highest during active treatment 
periods, which is completed for the majority of women by 6 months post-diagnosis 
[4] .  However, side-effects also persist well beyond the treatment period [6-8],  
despite overall improvements in quality of life (QoL) [9, 10].  Safe and effective 
evidence-based strategies are needed to prevent or attenuate treatment-related 
sequelae and to optimise the recovery of breast cancer survivors.  
 
Evidence to support the effectiveness of exercise programs in reducing symptoms and 
improving QoL after a cancer diagnosis comes from over 80 exercise intervention 
studies involving cancer survivors, particularly those with breast cancer. Synthesised 
in systematic reviews [11-18] and meta-analyses [19-22], results suggest that physical 
activity interventions implemented during and following treatment can prevent 
decline or improve cardio-respiratory fitness, body composition, skeletal health, 
immune function, strength and flexibility, body image, self-esteem, mood, and 
chemotherapy completion rates. These interventions have also been associated with 
reductions in hospitalisation duration, stress, depression, anxiety and the number and 
severity of side-effects, including nausea, fatigue and pain. Evidence from cohort 
studies also suggests a survival benefit among those who remain or become physically 
active following their diagnosis [23-25]. 
 
However, despite these benefits, the majority of breast cancer survivors remain or 
become insufficiently active following a breast cancer diagnosis [26-30]. Thus, we 
need to better understand how to assist women to become and stay appropriately 
active during and following breast cancer treatment. The majority of exercise 
intervention trials among women with breast cancer have evaluated interventions 
delivered in supervised, clinic-based settings, often in a group format [31]. While 
these have provided strong evidence of efficacy in controlled trials with selected 
volunteer samples, they tell us less about the extent to which such interventions might 
generalise to the very broad and heterogeneous population of women with breast 
cancer, or about the extent to which they could be integrated into clinical care [32].  
 
Exercise for Health (EfH) is a pragmatic trial that evaluates feasibility and 
effectiveness of two modes of exercise intervention delivery that, if successful, could 
be integrated within clinical practice.  The eight-month intervention was designed to 
assist women during active treatment periods (up to 6 months post-diagnosis), to more 
quickly and fully recover following treatment, and to develop the skills and 
confidence to become and stay physically active for the longer term.  The purpose of 
this paper is to describe the design and methods of the EfH trial and to evaluate the 
feasibility of implementation (recruitment and retention), the generalisability of 
findings (representativeness of sample) and to describe intervention participation. 
 
2. Trial Design 
EfH was a randomised controlled trial, evaluating an eight-month exercise 
intervention delivered either face-to-face or over the telephone by tertiary-qualified 
Exercise Physiologists/Kinesiologists, commencing six weeks post-surgery for newly 
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diagnosed breast cancer patients.  The trial (ACT RN: 012606000233527) was 
reviewed and approved by the Institutional Review Board (ie, Ethics Committee) at 
Queensland University of Technology and at each of the participating hospitals.  
 
2.1. Eligibility criteria 
Women with a first diagnosis of invasive breast cancer between October 2006 and 
June 2008, aged 20 to 69 years, and treated at one of four Brisbane hospitals were 
eligible for participation. These hospitals were purposely chosen as they represent the 
private and public Queensland hospitals with the highest caseloads, together treating 
28.4% of those diagnosed with breast cancer in Queensland in 2007.  To be eligible, 
women also had to reside within 30 km of the Brisbane central business district to 
enable participation in the face-to-face intervention group. Exclusions were made for 
women who were pregnant or lactating, were not willing to accept random 
assignment, had plans for additional surgery (e.g., breast reconstruction) during 
the study period, had poor understanding of written or spoken English, or had a 
medical condition that would prohibit participation in the exercise intervention 
(e.g., unstable hypertension).   
 
2.2. Recruitment process 
Breast Care Nurses and Physiotherapists at the participating hospitals were asked to 
introduce the trial to all women receiving surgery for breast cancer and to ascertain 
consent for contact details to be passed to researchers.  This typically occurred while 
patients were in hospital for breast surgery or during the first surgical follow-up visit. 
Researchers then contacted potential participants 3-4 weeks post-surgery to discuss 
the trial in more detail and to obtain informed consent. Eligibility criteria were 
confirmed during a screening telephone interview, and information relevant to the 
implementation of an exercise intervention was collected, including future treatment 
plans, the status of pre-existing co-morbid conditions (e.g. heart conditions, diabetes, 
asthma, arthritis), current medications and exercise history prior to diagnosis. Baseline 
assessment was scheduled during this call. 
 
2.3. Randomisation 
Following baseline assessment, women were randomised individually via a computer-
generated, unblocked, sequence of random numbers to obtain similar numbers of 
women in the face-to-face-delivered exercise intervention group (FtF), telephone-
delivered exercise intervention group (Tel) and usual-care group (UC).  
  
2.4. Exercise intervention 
The intervention was implemented by Tertiary-trained Exercise Physiologists who are 
allied health professionals with skills and experience in exercise science.  The 
Exercise Physiologists who worked on this study also underwent a 2-week training 
program, devised and developed by chief investigators, to ensure all staff had the 
required specialist skills for working with women with breast cancer and to ensure 
that program delivery was implemented in a standardised manner required for 
research. 
 
The eight-month exercise intervention encouraged women to exercise at least four 
days per week, accumulating at least 45 minutes of moderate-intensity physical 
activity on these days (Table 1).  Aerobic-based exercise was to be included in each 
session, while strength-based exercise was encouraged at least twice per week. To 
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arrive at this goal, intervention participants had 16 sessions scheduled with their 
designated Exercise Physiologist, during which time the intervention was gradually 
progressed by incorporating different exercise types and by increasing exercise 
intensity and duration (Table 1). While the overall goal of the program was the same 
for each participant, the exercise starting parameters and rate of progression towards 
the goal was individualised to account for the participant’s baseline functional 
capacity, the presence and severity of treatment-related side-effects, exercise 
preferences and previous exercise history.  
 
The Exercise Physiologists used a patient-centred approach by following the Chronic 
Disease Self-Management Intervention Model (CDSM) adapted from our previous 
work [33] to guide each session. The CDSM emphasises collaborative interactions, 
with the Exercise Physiologist offering support and guidance for increasing physical 
activity, while acknowledging the participant’s expertise in knowing what works best 
for her in the context of her life. Each session assessed exercise progression during the 
previous period and ascertained participant-report of presence or change in treatment-
related symptoms. In the instance that symptoms were adversely progressing, the 
participant was referred back to their breast care nurse, who then managed the 
participant according to usual care, which may have entailed referral to the treating 
clinician and/or physiotherapist.  No participants were stopped from participating in 
this trial though as a consequence of presence or change in symptoms. During the 
sessions with the Exercise Physiologist, exercise achievements in the previous period 
were acknowledged, barriers resolved, subsequent exercise goals discussed and 
necessary follow-up support identified, with all session details recorded in the 
participant’s case management folder. The responsibility for progress towards or 
maintenance of study goals was driven by the Exercise Physiologist during the first 
third of the eight-month intervention, shared by the participant and Exercise 
Physiologist during the second third, and the responsibility of the participant during 
the final third of the program. This approach allowed for women to be guided by the 
Exercise Physiologist during active treatment periods, when treatment-associated 
symptoms were most likely changing in type and/or severity. It allowed participants to 
develop exercise knowledge and confidence during the first part of the intervention, 
so that by the end, participants were aware of what and how much exercise they 
should be doing as well as what strategies they needed to optimise activity. Reduced 
reliance on the Exercise Physiologist was also facilitated by tapering the frequency of 
Exercise Physiologist contact over the eight-month period (once/week for 2 months, 
once/fortnight for 2 months and once/month for 4 months), and for those in the FtF by 
delivering the final two contacts by telephone.  Of note, the exercise intervention was 
the same for those in the FtF and Tel group, with only the mode of intervention 
delivery being different.  Caseloads for each Exercise Physiologist were also balanced 
with respect to FtF and Tel participants. 
 
Study workbook and exercise tracker 
Prior to intervention commencement, those in the exercise groups were mailed 
background information and a photograph of their assigned Exercise Physiologist (to 
help establish rapport between the Exercise Physiologist and the participant, 
particularly for those in the Tel group who never met their Exercise Physiologist face-
to-face), an exercise workbook and an exercise tracker and pen. The workbook and 
exercise tracker were mailed to all UC participants following study completion. 
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The exercise workbook (available on request) was developed by the study 
investigators with expertise in breast cancer, exercise science and behavioural science, 
and was used to supplement intervention sessions with the Exercise Physiologist.  The 
workbook contained information on a range of topics, including treatment-related 
side-effects, reasons for being active during treatment, exercise safety, types of 
activity and how much to do, exercise intensity and how to progress exercise. These 
topics were discussed during the first month of the program and were revisited as 
needed throughout the intervention. The workbook also contained a series of strength 
and flexibility-based exercises that were performed during face-to-face sessions or 
were talked through over the telephone. The exercise tracker was used by participants 
to plan and self-monitor weekly physical activity, but its use was not a compulsory 
component of the intervention.  
 
2.5 Usual care 
Those allocated to the usual care group participated in all data collection assessments 
(as described below) but did not receive any study exercise-intervention related 
material until study completion.  They may have received ad hoc information related 
to exercise following breast cancer from their treating hospital, breast cancer support 
group or other source.  If the usual care group questioned study assessors about 
exercise, they referred participants back to their breast cancer nurse for advice. 
 
2.6. Data collection: timing and outcomes assessed 
Three assessments were scheduled at: baseline/five weeks post-surgery (pre-
intervention); six months post-surgery (mid-intervention and following the period of 
more regular contact with the Exercise Physiologist for those in the exercise groups), 
and 12 months post-surgery (approximately two months post-intervention) (Figure 1).  
In this manner, we are able to compare study outcomes of those in this sample with 
those from representative, prospective cohort studies with similar 6- and 12-months 
post-diagnosis endpoints, while also being able to evaluate whether the intervention 
reduces treatment-related side-effects, optimises recovery and leads to longer-term 
behaviour change. Study outcome data were collected via clinical assessment and by 
completion of participant-administered and interviewer-administered surveys using 
previously validated protocols and instruments. The primary outcome for the study is 
QoL[34], while secondary outcomes include physical activity levels[35], functional 
capacity[36, 37], and presence and severity of treatment-related symptoms such as 
fatigue[38], pain[39] and lymphoedema[4]. All clinical assessments were conducted 
by an Exercise Physiologist blinded to participant study group, and participants were 
instructed to not reveal their allocation.  Information relating to participant 
characteristics (potential confounding variables) including personal (age, body mass 
index, socioeconomic status, number of children, working status, treating hospital), 
disease (type, tumour size and grade, stage and lymph node, oestrogen, progesterone 
and herceptin status) and treatment (chemotherapy, radiation therapy, hormone 
therapy and extent and laterality of surgery) characteristics was collected at baseline 
only via medical chart review or the participant-administered questionnaire.  
 
2.7. Sample size calculations 
A priori sample size calculations were based on the primary outcome, QoL, as 
measured by the Functional Assessment of Cancer Therapy, Breast (FACT-B+4) 
questionnaire [34]. Specifically, to detect a clinically important difference in overall 
QoL between groups or change over time of 8 units (standard deviation of change in 
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FACT-B+4 over 12 months = 10 units) [34]., with 90% power and 5% type I error 
(two tailed), a minimum of 40 women per group was required.  However, sample size 
was inflated by 20% to allow for attrition, and an additional 20% for multivariable 
modelling, yielding our target sample size of approximately 60 women per group. 
 
2.8. Statistical analysis 
Recruitment rates represent the number of consenting and participating women 
divided by the number of eligible women approached to participate.  Retention rates 
were calculated by dividing the number of participants who completed follow‐up 
testing by the number who completed baseline testing.  Participant characteristics 
were compared with data from the Queensland Cancer Registry to determine potential 
generalisability of study findings.  Baseline characteristics for those assigned to the 
intervention and usual care groups were compared to determine success or otherwise 
of the randomisation process.  Characteristics were described using mean and 
standard deviation for Normally-distributed, continuous outcomes; median, minimum 
and maximum for non-parametric continuous data; and proportions for categorical 
outcomes.  A priori, absolute baseline differences of approximately 10% for all 
personal, treatment and disease characteristics were considered clinically relevant.  
Intervention participation was calculated by describing the level of participation in the 
scheduled intervention sessions with the Exercise Physiologist using the median 
(minimum, maximum).  We considered a priori, that participation in at least 75% of 
these sessions was considered adequate exposure with an Exercise Physiologist to 
observe an intervention effect. 
 
Future analyses of intervention impact on primary and secondary outcomes will 
proceed according to intention-to-treat principles (n=194).  That is, participants will 
remain flagged according to their treatment allocation at baseline.  Missing data will 
not be imputed as they are unlikely to be missing at random. Multivariate, repeated-
measures models will consider group, time, and group by time interaction effects, 
adjusting for the influence of established and other identified confounders.  
Depending on how well assumptions are met, we anticipate using a generalised 
estimating equations framework for these analyses.  
 
3. Results  
3.1. Recruitment and retention 
Of the 402 names of potentially eligible participants received from the Breast Care 
Nurses at the treating hospitals (Figure 2), 21% were excluded due to not meeting the 
inclusion criteria.  Of the remaining 318 women, 63% were eligible and agreed to 
participate (n=200), 34% declined, and the remaining 3% could not be contacted (the 
proportion of ineligibles within the group who declined to participate or who could 
not be contacted is unknown).  Of the 200 women who gave informed consent, six 
women withdrew prior to baseline assessment, thus were not randomised.  The 
randomisation schedule led to 67, 67 and 60 women in the FtF, Tel and UC, 
respectively.  Fourteen additional women withdrew consent after baseline testing and 
randomisation (6, 4 and 4 in the FtF, Tel and UC, respectively), with 12 of these 
women withdrawing prior to or within the first 6 weeks of commencing the 
intervention.  Consequently, the overall (12-month) study retention rate was 93%.   
Women who withdrew (n=14) were of similar age, socioeconomic status (as defined 
by yearly income and education level) and had similar disease and treatment 
characteristics, including type of surgery, stage of disease, number of nodes examined 
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and number of positive nodes (data not shown), compared with those who maintained 
study participation through to final assessment. Study participants were on average 7 
years younger than the Queensland breast cancer population, with slightly larger 
tumour sizes (22mm compared with 20mm); however, disease type and number of 
nodes examined and number of positive nodes were similar (Table 2).   
 
3.2. Baseline characteristics  
On average, participants were aged 52.4 years (SD=8.5) and were overweight (mean 
body mass index=26.6+5.2kg/m2).  The majority (71.1%) were diagnosed with 
infiltrating ductal carcinoma, and 30.4% and 61.9% were classified as having Stage I 
and II+ disease, respectively (4.1% were classified as stage 0 and 3.6% were 
unknown).  Personal and diagnostic characteristics including age, BMI, 
socioeconomic status and type and stage of disease, were similar for participants in 
the FtF, Tel and UC groups (Table 3).  However, those in the Tel were more likely to 
be treated at a private hospital and to have oestrogen/progesterone-receptor-positive 
disease when compared with those in the UC.  Also, on average, the FtF were less 
likely to have HER2-positive breast cancer than the Tel and UC, the Tel was less 
likely to have a mastectomy than the FtF and UC, and the UC was less likely to be 
treated on the left side.  
 
3.3. Intervention participation 
Those in the FtF participated in a median of 14 sessions (min, max: 0, 16) with their 
Exercise Physiologist, with 82% participating in at least 75% of the schedule sessions.  
Those in the Tel participated in a median of 13 sessions (min, max: 3, 16) and 68% 
participated in 75% or more of the scheduled sessions.   
 
4. Discussion  
Substantial evidence derived from efficacy trials [20, 40] supports the integration of 
exercise during and following treatment for breast cancer. The EfH trial extends this 
work by evaluating two modes of delivering an evidence-based exercise intervention, 
along with an approach for recruitment and intervention implementation that could 
readily be taken up into practice.   Existing hospital-based Breast Care Nurses and 
Physiotherapists introduced the trial to women immediately following breast surgery, 
and the intervention was delivered by tertiary-qualified Exercise Physiologists in a 
way that could be government-funded within the existing health care system of 
Australia.  Further, in contrast to rigid intervention goals, the responsibility for 
planning, monitoring, and identifying and overcoming barriers to participation in 
regular exercise progressively shifted from the Exercise Physiologist to the participant 
during the eight-month intervention period.  This approach acknowledges the need for 
professional guidance when exercising during active treatment periods, but the need 
for participant buy-in to sustain behaviour change and subsequent benefits in the 
longer term.   
 
A recent review of 65 exercise intervention trials of 1-26 weeks duration (mostly 6-12 
weeks duration) for people with cancer, during or following treatment, found that the 
median uptake and completion rates were 63% (33-80%) and 87% (80-97%), 
respectively [41].  Despite approaching women during a period of intense emotional 
turmoil (within 4 weeks of breast surgery) and asking women to partake in an eight-
month intervention, we achieved similar recruitment (63%) and retention (93%) rates, 
indicating that the intervention was acceptable to and feasible for most.  Nonetheless 
Submitted to Contemporary Clinical Trials 9th Sept 2010 
9 
our experiences have highlighted the need for support from the health care team, 
specifically physician recommendation and Breast Care Nurse follow-up, in making 
exercise a priority in the lives of women with breast cancer, in particular women who 
do not have a history of participating in regular exercise.  Further, our experiences 
suggest that while introducing exercise early following a breast cancer diagnosis is a 
particularly sensitive challenge, it does have advantages.  Specifically, capturing the 
necessary health history for participation in an exercise intervention allows the 
participant to freely disclose information in a non-threatening environment and 
initiates rapport-building between participant and Exercise Physiologist.  
Additionally, exercising during active adjuvant therapy may minimise treatment-
associated symptoms [42, 43], and allows participants to develop confidence in their 
ability to exercise no matter what challenges they face. 
 
Our inclusion criteria were broad, with study feasibility and safety dictating a need for 
only a few exclusion criteria, specifically age, health and residence.  Compared with 
the Queensland breast cancer population, the EfH sample was, on average, seven 
years younger and had slightly larger tumours (on average 2mm larger).  However, 
these differences were considered minor, particularly since disease type, number of 
nodes examined and number of positive nodes were similar, suggesting future 
outcome findings will likely be generalisable to the wider urban breast cancer 
community.  Although not quantifiable, it is likely that the women who enrolled in the 
trial were more receptive to becoming or staying physically active compared with 
those who refused to take part.  If correct, then our ability to influence behaviour in 
the FtF and TG will be reduced, and those in the UC may be more likely to initiate or 
maintain physical activity on their own.  Both factors may bias the trial in the 
conservative direction by making it more difficult to observe change over time and 
differences between groups.  In that case, any positive results attributed to the exercise 
interventions will represent underestimates of true effect sizes.  We will be able to 
address this more directly when interview data regarding history of physical activity 
and tracking data become available.   
 
An important and novel aspect of the EfH trial is our ability to determine whether the 
mode of intervention delivery influences intervention effect.  The telephone-support 
intervention has the advantage of reaching women independent of place of residence 
and has possible cost advantages compared with face-to-face delivery of an exercise 
intervention. However, the magnitude of effect may be stronger when the intervention 
is delivered face-to-face, as the provision of support during exercise sessions may 
influence intensity and type of exercise undertaken.  It is also possible that participant 
characteristics (e.g., age, disease severity, treatment status) will influence outcomes, 
perhaps interacting with mode of delivery. Evaluation of moderators of outcome will 
be the subject of future analyses.  
 
Our ability to evaluate effect of mode of delivery will be influenced by the success of 
randomisation and balance in intervention participation between the intervention 
groups.  Groups were not perfectly balanced in numbers (67, 67, 60 in the FtF, Tel 
and UC, respectively); in retrospect block randomisation may have improved this 
balance.  However, there were only a few minor imbalances with respect to group 
characteristics, and these are unlikely to influence intervention effects given balance 
in other related characteristics.  For example, while the Tel group was more likely to 
be treated at a private hospital and less likely to receive a mastectomy compared with 
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the FtF and UC, rates for stage of disease, extent of axillary dissection and receipt of 
adjuvant therapy were similar between the groups.   Nonetheless, in future analyses 
we will assess the relationships between patient characteristics and outcomes of 
interest, and adjust for potential confounding as necessary.  From a group perspective, 
there was no clinical difference in intervention participation between those in the FtF 
and Tel groups, with a median of 14 and 13 sessions undertaken, respectively.  
However, 82% of those in the FtF, compared with 68% of those in the Tel group, 
received the predefined adequate intervention dose, with these rates being in line with 
those reported in other efficacy trials [41].  
 
In summary, the EfH trial was successful at recruiting a large sample that is mostly 
representative of the wider breast cancer population and will subsequently inform 
whether the mode of intervention delivery influences the outcomes under study.  Key 
strengths to the trial include the use of a real-world approach with high-quality study 
design characteristics, including intention-to-treat principles, assessors blinded to 
group allocation, translational recruitment and intervention features, and an adequate 
sample size.  The evidence-based exercise intervention under evaluation has exercise 
prescription features consistent with national physical activity guidelines [28], which 
also have been adopted by the Cancer Council Australia and the American Cancer 
Society.  The recruitment, retention and intervention participation results provide 
clear evidence of the potential interest women with breast cancer have in pursuing 
activities that may optimise their lives during and following treatment.  Subsequent 
analyses will explore the effect that EfH has on survivorship issues, including quality 
of life. It seems plausible that exercise may soon be viewed as a form of cancer 
treatment in its own right (e.g., may have an independent effect on survival [24, 44, 
45]) as well as a form of adjuvant therapy that optimises the success of treatment 
(e.g., may enhance chemotherapy compliance [46]).  Demonstrating an ability to 
deliver a translational and pragmatic exercise intervention to a generalisable sample of 
women with breast cancer will contribute significantly to the evidence base, 
supporting the integration of exercise into the care of women with breast cancer.   
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Table 1: Exercise parameters of the Exercise for Health intervention  
Frequency of exercise:   4+ times/week 
 All sessions included upper- and lower-body range of 
motion exercises as part of a warm-up and cool-down 
 Type Intensity Duration Frequency of 
sessions with 
Exercise 
Physiologist  
Weeks 1-4/month 1 Aerobic Low to 
moderate 
20-30 minutes Once/week 
Weeks 5-8/month 2 Aerobic 
with 
strength 
introduced 
Moderate 30-45 minutes Once/week 
Weeks 9-16/month 3-8 Aerobic 
and 
strength 
Moderate 
to high 
45+ minutes Once/fortnight 
Weeks 17+/month 5-8 Aerobic 
and 
strength 
Moderate 
to high 
45+ minutes Once/ month 
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Table 2: Baseline demographic and disease characteristics of Exercise for Health 
study participants (n=194) diagnosed between 2006 and 2008 compared with 
Queensland Cancer Registry data for breast cancers diagnosed among women in 2007 
(n=2469) 
Characteristic Study participants 
Median (min, max)  
Cancer Registry  
Median (min, max) 
Age at diagnosis (years) 52.0 (28, 69) 59 (24, 103) 
Breast cancer size (mm) 22.0 (0.1, 100) 20.0 (0, 185 
Number of nodes examined 7 (0, 29) 8 (0, 51) 
Number of positive nodes 0 (0, 21) 0 (0, 44) 
 n (%) n (%) 
Histologic type 
 Infiltrating ductal 
 Infiltrating lobular 
 Other 
 
138 (71.1) 
18 (9.3) 
38 (19.6) 
 
1757 (71.2) 
265 (10.7) 
447 (18.1) 
Source: Queensland Cancer Registry Data Collection, extracted 02-08-10. 
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Table 3: Baseline characteristics of randomised participants in the Exercise for Health 
trial by group allocation 
Baseline characteristics* Face to Face 
n=67 
n (%) 
Telephone 
n =67  
n (%) 
Control 
n= 60  
n (%) 
Personal characteristics    
Age (yrs) mean (SD) 51.2 (8.8) 52.2 (8.6) 53.9 (7.7) 
    
BMI mean (SD) 26.6 (4.5) 26.6 (5.3) 26.5 (5.8) 
Income    
< $52,000 
$52,000 - $93,599 
$93,600 - $130,000+ 
Missing 
17 (25.4) 
22 (32.8) 
13 (19.4) 
15 (22.4) 
21 (31.3) 
22 (32.8) 
18 (26.9) 
6 (9.0) 
19 (32.2) 
17 (28.8) 
13 (22.0) 
10 (16.9) 
Children    
Yes 
No 
Missing 
55 (82.1) 
12 (17.9) 
55 (82.1) 
12 (17.9) 
48 (80.0) 
10 (16.7) 
2 (3.3) 
Currently working     
No 
Full-time 
Part-time/casual/other 
Missing 
36 (53.7) 
16 (23.9) 
15 (22.4) 
36 (53.7) 
19 (28.4) 
7 (10.4) 
5 (7.4) 
32 (53.3) 
13 (21.7) 
13 (21.7) 
2 (3.3) 
Treating hospital    
Private Hospital 36 (53.7) 41 (61.2) 30 (50.0) 
Public Hospital 31 (46.3) 26 (38.8) 30 (50.0) 
Disease characteristics    
Type of Cancer    
Infiltrating ductal 
Infiltrating lobular 
Mixed ductal/lobular 
Carcinoma In-situ 
Other invasive carcinoma 
Missing 
48 (71.6) 
5 (7.5) 
5 (7.5) 
2 (3.0) 
3 (4.5) 
4 (6.0) 
48 (71.6) 
6 (9.0) 
4 (6.0) 
3 (4.5) 
5 (7.5) 
1 (1.5) 
42 (70.0) 
7 (11.7) 
4 (6.7) 
3 (5.0) 
3 (5.0) 
1 (1.7) 
Lymph Node Status    
Negative 
Positive 
None removed 
Missing 
34 (50.7) 
29 (43.3) 
3 (4.5) 
1 (1.5) 
38 (56.7) 
29 (43.3) 
0 (0.0) 
33 (55.0) 
23 (38.3) 
4 (6.7) 
Tumour Size (mm)**    
Mean (SD) 27.7 (18.5) 26.2 (18.2) 24.1 (16.0) 
Tumour Grading    
Overall Grade 
Grade 1 
Grade 2 
Grade 3 
Missing/Not available 
 
7 (10.4) 
27 (40.3) 
26 (38.8) 
7 (10.4) 
 
11 (16.4) 
29 (43.3) 
23 (34.3) 
4 (6.0) 
 
7 (11.7) 
25 (41.7) 
22 (36.7) 
6 (10.0) 
Stage    
0 2 (3.0) 3 (4.5) 3 (5.0) 
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* Baseline characteristics were assessed at 5 weeks post-surgery 
I 
II/III 
Unknown 
23 (34.3) 
38 (56.7) 
4 (6.0) 
18 (26.9) 
45 (67.2) 
1 (1.5) 
18 (30.0) 
37 (61.7) 
2 (3.3) 
Oestrogen/Progesterone status   
Positive 
Negative 
Discordant 
Unknown 
42 (62.7) 
13 (19.4) 
8 (11.9) 
4 (6.0) 
48 (71.6) 
8 (11.9) 
8 (11.9) 
3 (4.5) 
32 (53.3) 
8 (13.3) 
14 (23.3) 
6 (10.0) 
HER2 
Positive 
Negative 
Not performed 
Missing 
 
10 (14.9) 
53 (79.1) 
1 (1.5) 
3 (4.5) 
 
17 (25.4) 
45 (67.2) 
3 (4.5) 
2 (3.0) 
 
18 (30.0) 
34 (56.7) 
7 (11.7) 
1 (1.7) 
Treatment characteristics     
Chemotherapy    
Yes 
No 
39 (58.2) 
28 (41.8) 
40 (59.7) 
27 (40.3) 
29 (49.2) 
30 (50.8) 
Radiotherapy    
Yes 
No 
11 (16.4) 
56 (83.6) 
8 (11.9) 
59 (88.1) 
7 (11.9) 
52 (88.1) 
Hormone Therapy    
Yes 
No 
6 (9.0) 
61 (91.0) 
4 (6.0) 
63 (94.0) 
3 (5.1) 
56 (94.9) 
Herceptin     
Yes 
No 
2 (3.0) 
65 (97.0) 
3 (4.5) 
64 (95.5) 
3 (5.1) 
56 (94.9) 
Most Extensive Surgery    
Lumpectomy 
Mastectomy/Mod Rad 
Mastectomy 
41 (61.2) 
26 (38.8) 
52 (77.6) 
15 (22.4) 
34 (56.7) 
26 (43.3) 
Laterality of Surgery    
Right 
Left 
Bilateral 
32 (47.8) 
31 (46.3) 
4 (6.0) 
34 (50.7) 
32 (47.8) 
1 (1.5) 
35 (58.3) 
20 (33.3) 
5 (8.3) 
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Figure 1: Timeline of assessments and intervention for the Exercise for Health trial 
 
BC 
surgery 
5 weeks PS 6 months 
PS 
12 months 
PS 
8-month intervention 
Contact and consent 
Completion of baseline assessment 
Randomisation into one of three groups 
Start of intervention 
Assessment schedule: 
Time 1: 5 weeks post-surgery (PS) 
Time 2: 6 months PS 
Time 3: 12 months PS 
6-weeks PS 10 months  PS 
Submitted to Contemporary Clinical Trials 9th Sept 2010 
20 
Figure 2: Flow chart of participant recruitment and retention 
 
 
 
 
Time 2 
Enrollment 
(n = 200) 
Assessed for eligibility 
(n = 402) 
 
Time 1 
 
Time 3 
Random allocation 
Baseline assessment 
Five weeks post-surgery (pre-intervention) 
n = 194 
Excluded due to not meeting inclusion criteria (n = 84): 
Reasons: lives/moving outside the study region (n=53); too old (n=8); non-English 
speaking (n=5); diagnosed over three months ago (n=4); not first diagnosis (n=4); 
not invasive breast cancer (n=3); reconstructive surgery planned (n=3); other (n=4). 
Refused to participate (n = 108): Reasons: none given (n=50); other 
commitments/too busy (n=26); feel the program is not needed (n=15); not 
recovering/coping (n=8); not contactable (n=8); on holiday (n=1). 
Other reasons (n=10): numbers only were provided, no contact details 
provided for follow-up 
Withdrew prior to baseline testing (n=6): 
Reasons: too busy (n=3); unwell (n=2); moving away from area (n=1)  
Telephone (n = 67) Usual care (n = 60) Face-to-face (n = 67) 
Withdrew (n=12): 
Reasons: too busy (n=4); unhappy with allocation (n=2); 
not coping with treatment (n=2); unknown (n=2); unable 
to contact/passive withdrawal (n=2) 
Six months post-surgery 
(mid-way through intervention) 
n = 182 
12 months post-surgery 
(post-intervention) 
n = 180 
Withdrew (n=2): 
Reasons: no longer interested (n=2) 
Intention-to-treat  
n=194 
(Face-to-face, n=67; Telephone, n=67, Usual care, n=60) 
